Roche Pushing Personalized Medicine Concept In China
This article was originally published in PharmAsia News
Roche's diagnostics business, despite being the world's largest, has long been laying relatively low in China, particularly compared with its large drug business in the country. However, this is now changing as China continues to open up to targeted drugs and companion diagnostics, notably in oncology.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.